Browse the search results

Animal experiments show that the mosaic-type immunogen integrating key mutations from Omicron and other circulating variants elicits broad neutralization against divergent SARS-CoV-2 strains.

Bayesian survival analysis reveals comprehensive efficacy profile and mechanism of action for Sanofi-Pasteur’s CYD-TDV dengue vaccine, whereby vaccination acts as a silent, disease-free infection enhancing disease risk in seronegatives, but giving greater immunity in seropositives than two natural infections.

In a large discrete choice experiment, respondents from six European countries reveal preferences for global vaccine solidarity, where female, younger, more educated respondents are most likely to prioritise candidates from the Global South in their allocation choices for COVID-19 vaccines.

Prevaccination levels of transcriptional modules related to monocytes, dendritic cells, and other immune categories correlate with clinical malaria risk in RTS,S/AS01E-vaccinated African children, suggesting that certain monocyte subsets may inhibit RTS,S/AS01E-induced protective responses.

An immunopeptidomic-based pipeline provides a tool for the identification of cancer therapeutic targets and generation of cancer oncolytic vaccines.

The antibody accessibility of the leptospiral surface protein, LigB, provides a guide for the rational design of improved recombinant chimeric vaccine antigens displayed on a single domain scaffold.

Serum antibodies induced by CoronaVac tended to decrease over time, even though vaccinated with the homologous booster dose, and Delta and Omicron variants may be able to more efficiently evade the antibodies with time.

Circulating T follicular helper cells appear to be a promising biomarker candidate for monitoring vaccine efficacy in malaria vaccine trials.

Malaria pre-exposed volunteers exhibit large breadth of humoral immune responses, with strong variation between individuals, which might compromise vaccine-induced humoral immune response due to natural imprinting.

A replicating RNA vaccine platform generated significant immunity against SARS-CoV2 in mice and hamsters, and can be updated to target variants of concern.